Clinical Trial Update: Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating vincristine, topotecan, and cyclophosphamide with or without bevacizumab in young patients with refractory or first-recurrent e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Peripheral Primitive Neuroectodermal Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Topotecan hydrochloride (topotecan hydrochloride)
• Vincristine sulfate (VINCRISTINE SULFATE)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2014-09-02